Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association.

BACKGROUND Chemotherapy for metastatic breast cancer is palliative, and the optimal duration of therapy is unknown. We designed a trial to determine whether continuous treatment is superior to stopping treatment after a brief induction period and resuming treatment when the disease progresses. METHODS We treated 250 women with metastatic breast cancer with six courses of cyclophosphamide, doxorubicin, and fluorouracil given every three weeks. At the completion of this induction period, women whose disease either regressed or remained stable were randomly assigned to receive either continued treatment with cyclophosphamide, methotrexate, and fluorouracil (maintenance therapy) or no further treatment (observation) followed by treatment with cyclophosphamide, methotrexate, and fluorouracil when disease progression became evident (reinduction). RESULTS The combined rate of complete and partial responses after initial therapy was 30 percent (71 of 233 patients who could be evaluated; 95 percent confidence interval, 25 percent to 37 percent). In another 42 percent (98 patients), the disease remained stable. A total of 145 patients were randomized. Seventy-one were randomly assigned to the maintenance-therapy group, and 74 to the observation group. The median time to progression was 9.4 months for patients in the maintenance-therapy group and 3.2 months for patients in the observation group (P less than 0.001). After reinduction therapy, the median time to progression was 3.5 months. The median length of survival from the time of initial therapy was 14.8 months for all 250 patients; it was 21.1 months for the 71 patients in the maintenance-therapy group and 19.6 months for the 74 patients in the observation group (P = 0.67). Maintenance therapy was the most important determinant of the time before progression (P less than 0.001), but it was not associated with prolonged survival. The changes in performance status were similar in the patients in both groups, but nausea, vomiting, and mucositis were significantly more frequent in the maintenance-therapy group. CONCLUSIONS In patients with breast cancer who received induction chemotherapy for 18 weeks, subsequent continuous chemotherapy was associated with a significant prolongation of the time before progression as compared with those receiving no further therapy; overall survival, however, was not significantly different in the two groups.

[1]  Anna L. Brown,et al.  Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowe , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  J. Carmichael,et al.  Comparison of short-term and continuous chemotherapy (mitozantrone) for advanced breast cancer , 1990, The Lancet.

[3]  J. Garber,et al.  The use of chemotherapy in metastatic breast cancer. , 1989, Hematology/oncology clinics of North America.

[4]  R. Sanson-Fisher,et al.  Measuring quality of life in cancer patients. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  C. Moinpour,et al.  Quality of life end points in cancer clinical trials: review and recommendations. , 1989, Journal of the National Cancer Institute.

[6]  J. Doroshow,et al.  A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  R. Demicheli,et al.  Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicentre trial. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  M. Tattersall,et al.  Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies. , 1987, The New England journal of medicine.

[9]  A. Korzun,et al.  Chemotherapy versus chemoimmunotherapy (CAF v CAFVP v CMF each +/- MER) for metastatic carcinoma of the breast: a CALGB study. Cancer and Leukemia Group B. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  D. Hayes,et al.  CAF in metastatic breast cancer: standard therapy or another effective regimen? , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  G. Hortobagyi,et al.  Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: a prospective randomized study. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  R. Pugh,et al.  Short‐term chemotherapy of poor‐prognosis metastatic breast cancer with three non‐cross resistant chemotherapy regimens. A southwest oncology group study , 1987, Cancer.

[13]  E. Petru,et al.  On the relevance of "second-line" cytotoxic chemotherapy in patients with metastatic breast cancer resistant to standard combinations. , 1986, Wiener klinische Wochenschrift.

[14]  E. Korn Censoring distributions as a measure of follow-up in survival analysis. , 1986, Statistics in medicine.

[15]  G. Bonadonna,et al.  Current status of Milan adjuvant chemotherapy trials for node-positive and node-negative breast cancer. , 1986, NCI monographs : a publication of the National Cancer Institute.

[16]  E. Frei Curative cancer chemotherapy. , 1985, Cancer research.

[17]  R. Gelman,et al.  The eastern cooperative oncology group experience with cyclophosphamide, adriamycin, and 5‐fluorouracil (CAF) in patients with metastatic breast cancer , 1985, Cancer.

[18]  S. Raab,et al.  Randomized trial of cyclophosphamide, doxorubicin, and 5-fluorouracil alone or alternating with a "cycle active" non-cross-resistant combination in women with visceral metastatic breast cancer: a Southeastern Cancer Study Group project. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  A McMurray,et al.  Measuring the quality of life of cancer patients: the Functional Living Index-Cancer: development and validation. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  R. Simon,et al.  Comparison of four‐combination chemotherapy programs in metastatic breast cancer. Comparison of multiple drug therapy with cytoxan, 5‐fu and prednisone versus cytoxan and adriamycin, versus cytoxan, 5‐Fu and adriamycin, versus cytoxan, 5‐Fu and prednisone alternating with cytoxan and adriamycin , 1982, Cancer.

[21]  B. Hoogstraten,et al.  Adriamycin combinations in advanced breast cancer: A southwest oncology group study , 1982, Cancer.

[22]  C. Spurr,et al.  Adriamycin versus methotrexate in five‐drug combination chemotherapy for advanced breast cancer. A randomized trial , 1978, Cancer.

[23]  B. Hoogstraten,et al.  Adriamycin in combination for the treatment of breast cancer. A southwest oncology group study , 1978, Cancer.

[24]  J. Bull,et al.  A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy , 1978, Cancer.

[25]  R. Rubens,et al.  Assessment of response to therapy in advanced breast cancer. , 1977, British Journal of Cancer.